TICKERNERD
Menu
BCAXBCAXHealthcare · Biotechnology

BCAX Stock Forecast: Bicara Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$26
−5.02% on the day

The 15 Wall Street analysts covering Bicara Therapeutics, Inc. hold a median 12-month price target of $31 — +20.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
37 / 100
Median analyst target
$31
Analysts covering
15
Total return, dividends reinvested
1W
−7.4%
1M
−11.2%
YTD
+52.9%
1Y
+144.4%
From 52W high
−15.3%
From 52W low
+157.7%
$10
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Bicara Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
97
Value
81
Quality
63
Volatility
47
Accruals
44
Size
38
Revisions
27
Issuance
22
Growth
17

Momentum (97): The shares have been drifting up relative to others.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

The rank is the raw material. Whether the rules would actually own Bicara Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

BCAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26BCAXHigh $46Median $31Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says15 analysts
12 Buy3 Hold0 Sell
Low $16Median $31High $46

The green dot is the last close — the median target sits +20.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 May 2026Goldman SachsMaintainsNeutral$16 → $18
12 May 2026Morgan StanleyMaintainsOverweight$36 → $37
11 May 2026GuggenheimInitiatesBuy$42
31 Mar 2026CitizensReiteratesMarket Outperform—
31 Mar 2026Goldman SachsMaintainsNeutral—
31 Mar 2026HC Wainwright & Co.MaintainsBuy—
31 Mar 2026WedbushReiteratesOutperform—
31 Mar 2026Wells FargoMaintainsEqual-Weight—
25 Mar 2026B of A SecuritiesInitiatesBuy—
29 Jan 2026CitizensInitiatesMarket Outperform—
13 Jan 2026WedbushReiteratesOutperform—
8 Jan 2026BTIGInitiatesBuy—
18 Dec 2025MizuhoInitiatesNeutral—
11 Nov 2025Wells FargoMaintainsEqual-Weight—
22 Aug 2025HC Wainwright & Co.MaintainsBuy—
19 Aug 2025Piper SandlerInitiatesOverweight—
23 May 2025Wells FargoUpgradeEqual-Weight—
16 May 2025HC Wainwright & Co.MaintainsBuy—
17 Apr 2025Wells FargoInitiatesUnderweight—
7 Apr 2025HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

BCAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
11
Fundamentals

Bicara Therapeutics, Inc. (BCAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.4×

Cheaper than 68% of US stocks

Price / sales
—
Price / book
3.5×

Cheaper than 30% of US stocks

EV / EBITDA
−7.1×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 35% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−32.3%

Higher than 26% of US stocks

Return on assets
−21.1%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BCAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BCAXBicara Therapeutics, Inc.$1.8B
37
GENBGenerate Biomedicines, Inc.$1.8B
1
STOKStoke Therapeutics, Inc.$1.8B
50
SLSSELLAS Life Sciences Group, Inc.$1.8B
65
AGIOAgios Pharmaceuticals, Inc.$1.8B
81
DMRADamora Therapeutics, Inc.$1.7B
48
FTREFortrea Holdings, Inc.$1.8B
97
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCAX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest BCAX news & analysis

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors

GlobeNewsWire · 28 July 2026positive

Bicara Therapeutics announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender brings over 20 years of biotechnology corporate strategy and operating experience, while Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations.

Why it matters — A BCAX watcher would care because the company is adding two highly experienced leaders with deep backgrounds in biotech corporate strategy and oncology commercial operations to its board.

FAQ

Frequently asked questions about BCAX stock

What is the BCAX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Bicara Therapeutics, Inc. have a median 12-month price target of $31, with estimates ranging from $16 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCAX stock a buy right now?

Of the 15 analysts covering Bicara Therapeutics, Inc., 12 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bicara Therapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCAX?

As at 1 Aug 2026, Bicara Therapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).

Will BCAX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +20.4% from the last close, and Ticker Nerd's factor model ranks Bicara Therapeutics, Inc. 37 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCAX stock forecast for 2030?

No analyst covering Bicara Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $46 over the next 12 months.

How has BCAX stock performed over the past year?

Bicara Therapeutics, Inc. returned +144.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Bicara Therapeutics, Inc. do?

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors.

What is the latest news on BCAX?

The most recent item we track (GlobeNewsWire, 28 July 2026): "Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors". Bicara Therapeutics announced the appointments of Jeremy Bender, Ph.D., MBA and Christy Oliger to its Board of Directors. Dr. Bender brings over 20 years of biotechnology corporate strategy and operating experience, while Ms. Oliger brings more than 30 years of commercial and operating experience in global biopharmaceutical organizations.

Company

About Bicara Therapeutics, Inc.

Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors. Its primary program, ficerafusp alfa, is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-directed monoclonal antibody with a transforming growth factor beta (TGF-β) binding domain. This design targets EGFR-expressing tumor cells while modulating TGF-β signaling in the tumor microenvironment to overcome fibrotic barriers, enhance immune cell penetration, and promote deeper anti-tumor responses. The therapy is being advanced in clinical trials for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), particularly HPV-negative cases with high unmet need, in combination with pembrolizumab. Evaluation is also underway in metastatic colorectal cancer, both as monotherapy and in combinations, highlighting its potential across multiple EGFR- and TGF-β-driven solid tumor indications. Incorporated in 2018 and headquartered in Boston, Massachusetts, Bicara Therapeutics Inc. operates within the biotechnology sector, emphasizing oncology innovation through targeted tumor microenvironment modulation.

CEO Dr. Claire Mazumdar Clemon M.B.A., Ph.D. · 103 employees · United States · https://www.bicara.com